An aptamer capable of targeting EGFR and the mutant variant EGFRvIII would serve to be an ideal candidate for use in glioblastoma therapy, as their overexpression and mutation are prevalent in the majority of glioblastoma tumours [32]. Here, EGFR is linked to neoplasm.